Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Regulatory News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Block Listing Six Monthly Return

14 Sep 2020 16:30

RNS Number : 9441Y
4d Pharma PLC
14 September 2020
 

14 September 2020

 

4D pharma plc

 

(the "Company" or "4D")

 

Block Listing Six Monthly Return

 

Name of applicant:

4D Pharma plc

Name of scheme:

Block Admission for February 2020 warrants

Period of return:

From:

10 March 2020

To:

9 September 2020

Number of securities originally admitted at date of admission:

22,000,000 Ordinary Shares of 0.25p each on 10 March 2020

Balance of unallotted securities under scheme(s) from previous return:

22,000,000 Ordinary shares

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0 Ordinary shares

Less: Number of securities issued/allotted under scheme(s) during period:

0 Ordinary shares

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

22,000,000 Ordinary shares

 

Name of contact:

Duncan Peyton

Telephone number of contact:

Company Secretary (0113 895 0130)

 

 

Contact Information:

4D

Duncan Peyton, Chief Executive Officer +44 (0)113 895 0130

Investor Relations ir@4dpharmaplc.com

 

N+1 Singer - Nominated Adviser and Joint Broker +44 (0)20 7496 3000

Aubrey Powell / Justin McKeegan / Iqra Amin (Corporate Finance)

Tom Salvesen (Corporate Broking)

 

Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332 2500

Dominic Wilson / Phil Walker

 

Image Box Communications

Neil Hunter / Michelle Boxall +44 (0)20 8943 4685

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRBUGDCIBBDGGS
Date   Source Headline
2nd Aug 20217:00 amRNSTwo MRx0518 presentations accepted for ESMO 2021
29th Jul 20217:00 amRNS$30 Million Credit Facility with Oxford Finance
26th Jul 20211:00 pmRNSPassing of Chief Financial Officer John Beck
6th Jul 20217:00 amRNSPublication - LBP improves activity of CAR-T
29th Jun 20217:00 amRNSLadenburg Thalmann Healthcare Conference
22nd Jun 20217:00 amRNSConference presentation on LBP Manufacturing’
4th Jun 20217:00 amRNSAsthma trial Part A enrolment and program update
1st Jun 20218:52 amRNSTotal Voting Rights
24th May 202110:48 amRNSResult of AGM
24th May 20217:00 amRNSUpdate on Data for Phase II Study of Blautix
17th May 20217:00 amRNSPresentation of Blautix IBS Phase II at DDW 2021
19th Apr 20217:00 amRNSCollaboration with Parkinson’s UK
16th Apr 20217:00 amRNSDirectors’ Subscription for new Ordinary Shares
15th Apr 20215:00 pmRNSAnnual Financial Report
15th Apr 20217:00 amRNSParticipation in Jefferies Therapeutics Summit
12th Apr 20212:26 pmRNSHolding(s) in Company
7th Apr 20217:00 amRNSHow to Convert AIM Ordinary Shares into Nasdaq ADS
1st Apr 20217:00 amRNSFinal Results
26th Mar 20213:21 pmRNSHolding(s) in Company
25th Mar 202112:08 pmRNSHolding(s) in Company
25th Mar 20218:00 amRNSHolding(s) in Company
22nd Mar 20217:00 amRNSCompletion of Merger
18th Mar 20211:25 pmRNSResult of Meeting
17th Mar 20211:00 pmRNS4D Pharma Announces Private Placement
3rd Mar 20217:00 amRNSInvestor conference participation
1st Mar 20215:49 pmRNSExercise of Options and Total Voting Rights
1st Mar 20217:02 amRNSJohn Beck Appointed as Chief Financial Officer
1st Mar 20217:00 amRNSAppoints Paul Maier to the Board as NED
26th Feb 202112:52 pmRNSHolding(s) in Company
26th Feb 20217:02 amRNSPosting of Circular
26th Feb 20217:00 amRNSU.S. SEC Declares Registration Statement Effective
16th Feb 20217:00 amRNSMicrobiome Leaders Panel Event
8th Feb 20217:45 amRNSHolding(s) in Company
8th Feb 20217:00 amRNSOncology Clinical Collaboration
4th Feb 20212:55 pmRNSHolding(s) in Company
3rd Feb 20217:00 amRNSOncology Program Update
1st Feb 20212:10 pmRNSTotal Voting Rights
27th Jan 20217:00 amRNSHolding(s) in Company
25th Jan 20216:01 pmRNSHolding(s) in Company
21st Jan 20217:00 amRNSConference participation
30th Dec 20208:32 amRNSHolding(s) in Company
29th Dec 20205:17 pmRNSHolding(s) in Company
29th Dec 20202:24 pmRNSHolding(s) in Company
22nd Dec 20202:31 pmRNSHolding(s) in Company
18th Dec 20208:53 amRNSJoins MJFF-sponsored Parkinson’s study consortium
27th Nov 20203:42 pmRNSHolding(s) in Company
26th Nov 20207:09 amRNSRegistration Statement filed with SEC
23rd Nov 20207:00 amRNSLongevity extends Business Combination deadline
12th Nov 202012:18 pmRNSHolding(s) in Company
9th Nov 20206:21 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.